OMCL
Omnicell, Inc. NASDAQ Listed Aug 9, 2001$43.31
Mkt Cap $2.0B
52w Low $24.85
61.2% of range
52w High $55.00
50d MA $37.55
200d MA $37.07
P/E (TTM)
959.6x
EV/EBITDA
21.7x
P/B
1.6x
Debt/Equity
0.2x
ROE
0.2%
P/FCF
24.0x
RSI (14)
—
ATR (14)
—
Beta
0.86
50d MA
$37.55
200d MA
$37.07
Avg Volume
700.6K
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
590 East Middlefield Road · Mountain View, CA 94043 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | 0.33 | 0.55 | +66.7% | 45.51 | +0.0% | -5.3% | -9.0% | -6.0% | -4.5% | -5.2% | — |
| Feb 5, 2026 | TNS | 0.47 | 0.40 | -14.9% | 39.08 | -1.5% | -5.1% | -6.6% | -0.2% | -3.2% | -7.4% | — |
| Oct 30, 2025 | TNS | 0.36 | 0.51 | +41.7% | 33.58 | +0.4% | -0.0% | -0.6% | +2.7% | +6.4% | +6.5% | — |
| Jul 31, 2025 | TNS | 0.31 | 0.45 | +45.2% | 31.01 | -0.9% | -4.0% | -1.9% | -1.6% | +0.3% | +0.1% | — |
| May 6, 2025 | TNS | 0.16 | 0.26 | +62.5% | 25.66 | +0.0% | -4.0% | -1.1% | +0.5% | +7.0% | +9.1% | — |
| Feb 6, 2025 | TNS | 0.57 | 0.60 | +5.3% | 39.43 | +0.2% | +1.9% | +7.5% | +4.6% | +2.7% | +2.0% | — |
| Oct 30, 2024 | TNS | 0.41 | 0.56 | +36.6% | 53.05 | -0.9% | -8.3% | -8.3% | -8.6% | -6.1% | -1.0% | — |
| Aug 1, 2024 | TNS | 0.16 | 0.51 | +218.8% | 38.85 | +1.9% | +1.0% | +3.0% | +6.4% | +0.5% | +3.5% | — |
| May 2, 2024 | TNS | -0.08 | 0.03 | +137.5% | 29.29 | +2.0% | +2.9% | +2.4% | +3.4% | +2.3% | +3.3% | — |
| Feb 8, 2024 | TNS | 0.17 | 0.33 | +94.1% | 29.10 | -3.0% | -5.8% | -0.7% | -1.7% | -4.7% | -2.7% | — |
| Nov 2, 2023 | TNS | 0.45 | 0.62 | +37.8% | 29.24 | +2.0% | +4.1% | +0.9% | +5.3% | +5.7% | +3.4% | — |
| Aug 1, 2023 | TNS | 0.28 | 0.57 | +103.6% | 61.70 | +1.7% | +4.7% | +3.5% | +5.3% | +5.8% | +4.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $45.51 | $45.51 | +0.0% | -5.3% | -9.0% | -6.0% | -4.5% | -4.3% |
| Apr 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $36.65 | $36.91 | +0.7% | -0.8% | +2.0% | +2.7% | +24.2% | +17.6% |
| Feb 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $39.08 | $38.51 | -1.5% | -5.1% | -6.6% | -0.2% | -3.2% | -7.4% |
| Feb 2 | Benchmark | Maintains | Buy → Buy | — | $48.50 | $49.09 | +1.2% | +0.4% | -5.1% | -3.7% | -19.4% | -23.6% |
| Jan 8 | KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | — | $47.45 | $49.90 | +5.2% | +6.6% | +6.9% | +7.9% | +8.3% | +6.9% |
| Jan 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $45.14 | $45.14 | +0.0% | +4.0% | +4.3% | +5.1% | +12.1% | +12.4% |
| Dec 9 | BofA Securities | Maintains | Neutral → Neutral | — | $43.55 | $44.00 | +1.0% | -0.1% | +1.0% | -0.6% | +0.7% | -0.6% |
| Dec 9 | Benchmark | Maintains | Buy → Buy | — | $43.55 | $44.00 | +1.0% | -0.1% | +1.0% | -0.6% | +0.7% | -0.6% |
| Oct 31 | Benchmark | Maintains | Buy → Buy | — | $33.58 | $33.72 | +0.4% | -0.0% | -0.6% | +2.7% | +6.4% | +6.5% |
| Aug 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.83 | $30.63 | -0.6% | +0.0% | +2.3% | +1.7% | +2.1% | +2.8% |
| Jul 21 | Wells Fargo | Maintains | Overweight → Overweight | — | $26.88 | $27.08 | +0.7% | +4.3% | +5.1% | +4.9% | +4.7% | +5.2% |
| Jul 14 | BofA Securities | Maintains | Neutral → Neutral | — | $28.69 | $28.24 | -1.6% | -3.9% | -5.1% | -3.2% | -2.5% | -6.3% |
| May 23 | BofA Securities | Maintains | Neutral → Neutral | — | $28.84 | $28.33 | -1.8% | -2.1% | +2.7% | +1.8% | +3.4% | +5.3% |
| May 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $28.84 | $28.33 | -1.8% | -2.1% | +2.7% | +1.8% | +3.4% | +5.3% |
| May 14 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $28.00 | $29.48 | +5.3% | +2.6% | +0.3% | -0.1% | -0.5% | +2.8% |
| May 7 | Benchmark | Maintains | Buy → Buy | — | $25.66 | $25.67 | +0.0% | -4.0% | -1.1% | +0.5% | +7.0% | +9.1% |
| May 7 | BofA Securities | Maintains | Neutral → Neutral | — | $25.66 | $25.67 | +0.0% | -4.0% | -1.1% | +0.5% | +7.0% | +9.1% |
| May 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $25.66 | $25.67 | +0.0% | -4.0% | -1.1% | +0.5% | +7.0% | +9.1% |
| Apr 17 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $30.95 | $30.35 | -1.9% | -2.2% | -4.2% | -3.3% | -0.8% | +0.8% |
| Mar 20 | JP Morgan | Maintains | Neutral → Neutral | — | $34.70 | $34.25 | -1.3% | +0.5% | -2.2% | +1.3% | -0.7% | -0.7% |
| Mar 13 | BofA Securities | Maintains | Neutral → Neutral | — | $33.34 | $33.47 | +0.4% | -3.2% | -1.0% | -0.4% | -1.2% | +4.1% |
| Feb 4 | Benchmark | Maintains | Buy → Buy | — | $43.42 | $43.06 | -0.8% | +1.0% | +2.2% | -9.2% | -7.5% | -2.3% |
| Jan 13 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $42.28 | $41.79 | -1.2% | +0.1% | +0.1% | +2.0% | -0.3% | +0.7% |
| Jan 6 | BofA Securities | Maintains | Neutral → Neutral | — | $45.32 | $45.09 | -0.5% | -1.3% | -4.3% | -4.9% | -6.7% | -6.6% |
| Nov 21 | JP Morgan | Maintains | Neutral → Neutral | — | $41.82 | $42.23 | +1.0% | +5.5% | +9.3% | +9.9% | +8.7% | +15.9% |
| Oct 31 | BofA Securities | Downgrade | Buy → Neutral | — | $53.05 | $52.56 | -0.9% | -8.3% | -8.3% | -8.6% | -6.1% | -1.0% |
| Oct 31 | Craig-Hallum | Maintains | Buy → Buy | — | $53.05 | $52.56 | -0.9% | -8.3% | -8.3% | -8.6% | -6.1% | -1.0% |
| Oct 31 | Barclays | Maintains | Equal Weight → Equal Weight | — | $53.05 | $52.56 | -0.9% | -8.3% | -8.3% | -8.6% | -6.1% | -1.0% |
| Oct 14 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $42.62 | $42.85 | +0.5% | +0.3% | -0.6% | -0.1% | -2.8% | -3.6% |
| Oct 9 | Benchmark | Maintains | Buy → Buy | — | $43.04 | $43.00 | -0.1% | -0.2% | -2.1% | -1.0% | -0.7% | -1.5% |
| Aug 23 | JP Morgan | Maintains | Neutral → Neutral | — | $42.52 | $42.95 | +1.0% | +5.4% | +6.8% | +6.8% | +6.3% | +6.4% |
| Aug 2 | BofA Securities | Maintains | Buy → Buy | — | $38.85 | $39.60 | +1.9% | +1.0% | +3.0% | +6.4% | +0.5% | +3.5% |
| Aug 2 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $38.85 | $39.60 | +1.9% | +1.0% | +3.0% | +6.4% | +0.5% | +3.5% |
| Aug 2 | Barclays | Upgrade | Underweight → Equal Weight | — | $38.85 | $39.60 | +1.9% | +1.0% | +3.0% | +6.4% | +0.5% | +3.5% |
| Jul 15 | Benchmark | Maintains | Buy → Buy | — | $26.55 | $26.54 | -0.0% | -0.4% | +3.8% | +7.9% | +3.7% | +3.7% |
| May 3 | Benchmark | Maintains | Buy → Buy | — | $29.29 | $29.87 | +2.0% | +2.9% | +2.4% | +3.4% | +2.3% | +3.3% |
| Apr 30 | Benchmark | Maintains | Buy → Buy | — | $27.40 | $26.95 | -1.6% | -2.2% | -0.8% | +6.9% | +10.0% | +9.4% |
| Feb 9 | Benchmark | Maintains | Buy → Buy | — | $29.10 | $28.23 | -3.0% | -5.8% | -0.7% | -1.7% | -4.7% | -2.7% |
| Feb 9 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $29.10 | $28.23 | -3.0% | -5.8% | -0.7% | -1.7% | -4.7% | -2.7% |
| Nov 3 | Wells Fargo | Upgrade | Underweight → Equal Weight | — | $29.24 | $29.82 | +2.0% | +4.1% | +0.9% | +5.3% | +5.7% | +3.4% |
| Nov 3 | BTIG | Downgrade | Buy → Neutral | — | $29.24 | $29.82 | +2.0% | +4.1% | +0.9% | +5.3% | +5.7% | +3.4% |
| Nov 3 | Piper Sandler | Upgrade | Neutral → Overweight | — | $29.24 | $29.82 | +2.0% | +4.1% | +0.9% | +5.3% | +5.7% | +3.4% |
| Oct 11 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $45.81 | $44.85 | -2.1% | -2.4% | -6.2% | -8.0% | -7.8% | -7.5% |
| Oct 3 | Benchmark | Maintains | Buy → Buy | — | $45.16 | $44.60 | -1.2% | -1.7% | -2.7% | -3.3% | -4.3% | -3.0% |
| Sep 26 | Wells Fargo | Maintains | Underweight → Underweight | — | $48.50 | $47.13 | -2.8% | -6.0% | -8.0% | -6.7% | -7.1% | -6.9% |
| Aug 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $63.88 | $63.88 | +0.0% | +1.7% | +2.2% | +0.7% | +2.5% | +0.5% |
| Aug 2 | Benchmark | Maintains | Buy → Buy | — | $61.70 | $62.76 | +1.7% | +4.7% | +3.5% | +5.3% | +5.8% | +4.2% |
| Aug 2 | Piper Sandler | Downgrade | Overweight → Neutral | — | $61.70 | $62.76 | +1.7% | +4.7% | +3.5% | +5.3% | +5.8% | +4.2% |
| Jul 31 | Benchmark | Maintains | Buy → Buy | — | $62.96 | $62.96 | +0.0% | +0.3% | -2.0% | +2.6% | +1.5% | +3.2% |
| Jul 20 | Wells Fargo | Downgrade | Overweight → Underweight | — | $67.42 | $65.30 | -3.1% | -6.7% | -6.3% | -7.7% | -7.2% | -7.7% |
No insider trades available.
8-K
Omnicell Inc -- 8-K Filing
Omnicell raised its full-year 2026 non-GAAP EBITDA and EPS guidance following strong first-quarter results, while advancing customer engagement for its Titan XT and OmniSphere products.
Apr 28
8-K
Omnicell Inc -- 8-K Filing
Omnicell announced its fourth quarter and full-year 2025 financial results, demonstrating performance for the healthcare technology company focused on autonomous medication management solutions.
Feb 5
Data updated apr 26, 2026 5:21pm
· Source: massive.com